多柔比星脂质体联合卡铂治疗晚期或复发转移子宫内膜癌疗效分析

Effect of Pegylated Liposomal Doxorubicin Combined with Carboplatin in Treating Primary Advanced or Relapsed/Metastatic Endometrial Cancer

目的评价多柔比星脂质体联合卡铂治疗晚期或复发转移子宫内膜癌的临床疗效及安全性。方法 21例晚期或复发转移子宫内膜癌患者,给予多柔比星脂质体[30 mg·(m^2)^(-1)]+卡铂(AUC=5)联合化疗,每3周为1个周期,共6个周期,评价化疗有效率、无进展生存时间及不良反应。结果 21例患者中,完全缓解患者2例,部分缓解患者10例,有效率(ORR)为57.1%,无进展生存时间(PFS)中位时间为9.2个月。主要不良反应为血液毒性及胃肠道反应。仅1例患者出现Ⅳ度白细胞减少,Ⅲ度白细胞减少、血红蛋白减少、血小板减少分别为3,1,1例,17例患者出现胃肠道反应,其中Ⅰ度12例,Ⅱ度5例,3例出现口腔黏膜炎,1例发生手足综合征,8例出现脱发,1例发生肝脏毒性,未观察到肾脏毒性和心脏毒性反应。结论多柔比星脂质体联合卡铂治疗晚期或复发转移子宫内膜癌有效率较高,不良反应轻,可作为这类患者的挽救化疗方案。

Objective To investigate the effect and security of pegylated liposomal doxorubicin combined with carboplatin in patients with primary advanced or relapsed/metastatic endometrial cancer.Methods Twenty-one patients with advanced or relapsed/metastatic endometrial cancer received pegylated liposomal doxorubicin[30 mg·(m2)-1]+carboplatin(area under curve 5)every 3 weeks for 6 cycles.The response rate,progression-free survival and the toxicity profile were evaluated.Results Two patients had complete responses and 10 patients had partial responses in the 21 patients,for an overall response rate of 57.1%.The median progression-free survival was 9.2 months.The major adverse reactions were haematological toxicity and gastrointestinal reactions.Grade 4 leukopenia was reported in only one patient.Grade 3 leukopenia,anemia,and thrombopenia were observed in 3,1,and 1 of the patients.Grade 1 gastrointestinal reactions occurred in 12 patients,whereas 5 patients experienced grade 2.Other relevant toxicities were stomatitis in 3 patients,palmoplantar erythrodysesthesia in 1 patient,hair loss in 8 patients,and liver toxicity in 1 patient.No renal toxicity and cardiac toxicity were recorded.Conclusion The combination of pegylated liposomal doxorubicin and carboplatin shows good activity and favourable toxicity,and it can serve as a better chemotherapy of patients with advanced or relapsed/metastatic endometrial cancer.